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 Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine:
neurohormonal aspects of recreational ‘ecstasy’
Andrew C. Parrotta,b
Most research into 3,4-methylenedioxymethamphetamine
(MDMA) has debated its psychobiological effects in relation
to neurotransmission. This article debates the contributory
roles of the neurohormones oxytocin and cortisol for their
psychobiological effects in humans. The empirical literature
on these neurohormones is reviewed and suggestions for
future research outlined. Acute MDMA or ‘ecstasy’ can
generate increased levels of oxytocin and cortisol, and
these neurohormonal changes may be important for its
mood-enhancing and energy-activation effects in humans.
However, an initial finding of enhanced sociability
correlating with oxytocin levels has not been replicated.
Potential reasons are debated. There may be dynamic
interactions between the two neurohormones, with greater
activation under cortisol, facilitating stronger positive
feelings under oxytocin. Chronic regular use of MDMA can
adversely affect cortisol in several ways. Regular users
show increased cortisol in 3-month hair samples, changes
to the cortisol awakening response, and indications of
greater daily stress. Furthermore, these cortisol findings
suggest changes to the hypothalamic–pituitary–adrenal
axis. The effects of chronic MDMA usage on oxytocin still
need to be investigated. It is concluded that the
neurohormones oxytocin and cortisol contribute in various
ways to the psychobiological effects of recreational
ecstasy/MDMA. Behavioural Pharmacology 27:649–658
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA) is a ring-
substituted methamphetamine derivative and a powerful
central nervous system stimulant. Its acute administration
leads to pronounced psychophysiological arousal and a range
of heightened mood states (Meyer, 2013; Parrott, 2013a;
Taurah et al., 2014; McCann and Ricaurte, 2014;White, 2014).
Neurochemically, MDMA is an indirect agonist for serotonin,
noradrenaline and dopamine, and it also affects several other
neurotransmitter systems (McDowell and Kleber, 1994;
Ricaurte et al., 2000; Green et al., 2003; Roger-Sanchez et al.,
2016). Empirical studies and theoretical reviews have focussed
primarily on these neurochemical properties and debated its
psychological effects in relation to serotonin and other neu-
rotransmitters (Kish et al., 2010; Benningfield and Cowan,
2013; Meyer, 2013; Parrott, 2013a, 2013b; McCann and
Ricaurte, 2014).
MDMA also affects the hypothalamic–pituitary–adrenal
(HPA) axis and stimulates the release of several neuro-
hormones. Hence, an acute dose of MDMA leads to
significant increases in cortisol levels (Dumont and
Verkes, 2006; Morefield et al., 2009), whereas regular
drug users show altered cortisol rhythms (Gerra et al.,
2003; Parrott et al., 2014a, 2014b; Wetherell and
Montgomery, 2014). Given the central role of the HPA
axis for homeostasis and everyday well-being, these
changes to cortisol may contribute to many of the psy-
chobiological sequelae of MDMA (Parrott, 2009; White,
2014). In the past 10 years, oxytocin has become of
increasing interest to MDMA researchers. Acute MDMA
administration stimulates the release of oxytocin, and it
has been hypothesized that this neurohormone may
underlie its mood-enhancing and prosocial properties
(McGregor et al., 2008; Dumont et al., 2009; Frokjaer
et al., 2014; Kamilar-Britt and Bedi, 2015). The core aim
of this review is to analyse and debate the contributory
roles of these two neurohormones for the psychobiolo-
gical effects of MDMA in humans. The secondary aim is
to suggest interesting questions for future research.
Psychobiological aspects of recreational ecstasy/
MDMA
There are two main reasons for using ecstasy/MDMA as a
recreational stimulant drug. First, it boosts physical acti-
vation, and second it can intensify positive mood states.
An acute dose of MDMA generates a pronounced
increase in heart rate, along with other indices of sym-
pathomimetic activation. Hysek et al. (2012) reported that
125 mg oral MDMA generated a mean heart rate increase
of + 26.1 bpm over baseline, together with parallel
Review article 649
0955-8810 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/FBP.0000000000000262
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
increases in systolic and diastolic blood pressure. This
heightened arousal can facilitate prolonged periods of
dancing, so that there is a strong association between
recreational ecstasy/MDMA and all-night clubbing. In an
Internet survey, 94% reported that they danced when they
were on ecstasy/MDMA (Parrott et al., 2006), whereas
many dance for prolonged periods until they are exhausted
(Suy et al., 1999). MDMA is also effective at generating
euphoric moods. Cohen (1998) interviewed recreational
users about its subjective effects, and one user reported
that ‘ecstasy is more or less a happy speed’ (speed being
the street name for amphetamine). Other interviewees
described sensory enhancement, feelings of pleasure or
elation (Cohen, 1998). In another interview study, it was
reported that ecstasy/MDMA led to ‘Loads of energy to
dance. Buzzing. Loved everyone’ (Parrott, 2010). Positive
mood profiles also emerged when dance clubbers were
assessed using mood questionnaires (Parrott and Lasky,
1998; Morefield et al., 2009). In acute-dose placebo-
controlled laboratory studies, significant increases in alert-
ness, elation and euphoria were also reported (Liechti et al.,
2001; Bedi et al., 2010; Kirkpatrick et al., 2012).
There are, however, potential dangers from the psycho-
physiological overactivation induced by stimulant drugs
(Laviola et al., 1999; Cruickshank and Dyer, 2009; Parrott,
2015). In relation to acute mood, the heightened stimulation
induced by MDMA can generate feelings of panic, anxiety,
paranoia or depersonalization – hence the following sub-
jective reports by recreational users: ‘Out of control. Too
much extra energy’; ‘I had a bad experience. I felt like I was
surrounded by water and drowning’ (Cohen, 1998). In
laboratory studies, acute doses of MDMA can generate sig-
nificant feelings of anxiety, loneliness, feeling jittery and ‘bad
drug effect’ (Liechti et al., 2001: Bedi et al., 2010; Kirkpatrick
et al., 2012). Psychophysiological adverse effects can include
‘Twitching and shaking of the leg’; ‘Chews his mouth and
lips all night’ (Parrott, 2010). The medical dangers of
MDMA include cardiac damage, renal problems, liver
damage and hyperthermia (Hall and Henry, 2006; Greene
et al., 2009; White, 2014). Neurocognitive and psychobiolo-
gical abreactions include memory deficits, higher cognitive
deficits, reduced social intelligence, disrupted sleep archi-
tecture and sleep apnoea, reduced immunocompetence,
increased pain sensitivity, and a range of psychiatric issues
(Kemmerling et al., 1996; Schifano et al., 1998; McCann et al.,
2000; Parrott, 2001, 2013a, 2013b; Fisk et al., 2005; Reay et al.,
2006; McCann and Ricaurte, 2007, 2014; Montgomery et al.,
2010; Brière et al., 2012; Meyer, 2013; White, 2014). There is
a great deal of individual variation in these acute reactions,
leading to the question of why some individuals seem quite
sensitive, whereas others are more robust. Numerous factors
may be important, including premorbid personality, sex, and
patterns of drug usage. However, another key factor may be
the HPA axis and neurohormonal integrity, as any individual
differences in baseline neurohormonal levels and/or
reactivity may influence the development of acute and
chronic psychobiological responses to psychoactive drugs.
Acute MDMA and oxytocin
Dumont and Verkes (2006) reviewed human acute-dose
MDMA studies and noted that, although 12 studies had
investigated cortisol, and four had assessed prolactin,
none had measured oxytocin. The first human study of
oxytocin was undertaken by Wolff et al. (2006), who took
urine samples before and after clubbing from dance
clubbers. The dancers with MDMA in their urine
demonstrated an increase in oxytocin after clubbing
(from 1.28 at baseline to 1.43 pmol/l), whereas nonusers
showed reduced oxytocin (from 1.23 at baseline to
1.16 pmol/l after clubbing). Wolff et al. (2006) also found
changes in vasopressin and urine osmotality, which were
debated in relation to the increased risk for potentially
fatal cerebral oedema. Emanuele et al. (2006) offered a
broader psychosocial–psychosexual interpretation for
these oxytocin findings. In a detailed commentary on
Wolff et al. (2006), they suggested that ‘Induction of
vasopressin and oxytocin release following MDMA
assumption could also account for several sociosexual
behavioural effects… including attachment and trust…
sexual arousal... and libido’. McGregor et al. (2008)
reviewed the empirical evidence for oxytocin being
involved in the prosocial and prosexual behaviours of
laboratory animals. They noted that this social neuro-
peptide was involved in reinforcement and dependency
on other psychoactive drugs (e.g. opiates, alcohol) and
recommended further research with MDMA.
In the first laboratory study into oxytocin, Dumont et al.
(2009) found that 100mg oral MDMA generated robust
increases in oxytocin and subjective prosocial feelings.
They further noted that the prosocial feelings were sig-
nificantly associated with oxytocin levels. Furthermore,
these positive correlations with oxytocin were stronger
that those found with plasma MDMA (Table 1). These
findings supported the predicted role of oxytocin in
relation to the prosocial effects of ecstasy/MDMA
(McGregor et al., 2008). However, subsequent studies
have generally failed to replicate this finding. Hysek et al.
(2012) found that ‘Reading the Mind in the Eyes’ test was
affected in complex ways by MDMA, with enhanced
accuracy for positive social stimuli, reduced accuracy for
negative emotional stimuli, and no change for neutral
stimuli. Plasma oxytocin levels were significantly
increased after MDMA, although the increased oxytocin
levels were not associated with any of the prosocial feel-
ings or behaviours (Table 1). Schmid et al. (2014) com-
pared the acute effects of 75mg oral MDMA and 40mg
oral methylphenidate in 30 volunteers. MDMA was found
to enhance empathy for positively emotionally charged
situations and increase feelings of openness and trust,
whereas these effects were not found with methylpheni-
date. MDMA also increased oxytocin and cortisol levels
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significantly, whereas methylphenidate increased cortisol
but not oxytocin. However, there were no significant
correlations between any of the emotional and psycho-
social gains, and the increased levels of oxytocin.
Hysek et al. (2014) administered oral doses of 125mg
MDMA to 32 healthy volunteers, which included equal
numbers of men and women. Oxytocin, cortisol and prolactin
were significantly increased (each at P<0.001). Performance
levels on the Multifaceted Empathy test, the Social Values
Orientation test, and the Facial Affect Recognition test were
affected in complex ways. MDMA impaired the accuracy of
emotional recognition overall in comparison with placebo,
regardless of emotional valence, although this deficit mainly
reflected an impairment in the accuracy of perceiving nega-
tive valence faces (e.g. fearful, angry, or disgusted). MDMA
increased explicit and implicit emotional empathy ratings
overall, although these increases were mainly for positive
valence stimuli rather than for negative valence stimuli;
again, there were sex differences. On the social orientation
measure, MDMA increased prosociality overall, although this
was primarily due to an increase in male volunteers, with
female volunteers showing no change. Overall, this assess-
ment battery showed a surprisingly complex pattern of
changes, with increased positive perceptions on some mea-
sures, along with neutral or negative findings on other
measures. Despite the large number of dependent variables,
none were associated with the changes in oxytocin, cortisol or
prolactin, Hysek et al. (2014) commented that ‘No correla-
tions were found between the effects of MDMA on emo-
tional recognition and the endocrine effects of MDMA’.
Kuypers et al. (2014) compared four treatment conditions:
75mg oral MDMA with/without 20mg oral pindolol (a
partial 5-HT1A receptor blocker), nasal oxytocin spray, and
placebo. The oxytocin spray led to plasma oxytocin levels
2.5 times higher than placebo (P= 0.033), 75mg oral
MDMA led to plasma oxytocin levels 2.3 times higher than
placebo (P=0.071), whereas MDMA+pinidol led to an
oxytocin increase 2.0 times higher than placebo (P= 0.071).
Hence, although the increases in oxytocin under the two
MDMA conditions were nonsignificant, they were statis-
tically borderline and in the predicted direction (note: both
MDMA conditions generated highly significant increases
in cortisol). MDMA led to an increase in emotional
empathy, but left the measures of cognitive empathy,
reciprocity and trust unaffected. Finally, the changes in
emotional empathy were not statistically related to plasma
oxytocin levels (Table 1).
Kirkpatrick et al. (2014a, 2014b) compared the effects of
75 mg and 125 mg oral MDMA, nasal oxytocin and pla-
cebo in 14 abstinent recreational ecstasy/MDMA users.
The lower dose of MDMA led to a slight (nonsignificant)
trend for increased oxytocin, whereas the 125 mg dose of
MDMA led to a pronounced oxytocin increase, with
values 450% higher than those of placebo. In cardiovas-
cular terms, MDMA led to significant dose-related
increases in heart rate and blood pressure. The higher
dose of MDMA also led to significant increases in self-
rated euphoria, sociability and friendliness. However,
these positive mood changes were independent of oxy-
tocin levels, with Kirkpatrick et al. (2014b) noting that
none of the subjective or cardiovascular responses to
MDMA were significantly correlated with plasma oxy-
tocin. To summarize, the early finding of an association
between oxytocin and prosocial feelings (Dumont et al.,
2009) has not been confirmed in subsequent studies
(Hysek et al., 2012, 2014; Kuypers et al., 2014; Schmid
et al., 2014; overview in Table 1).
Acute MDMA and cortisol
In their review of acute MDMA research, Dumont and
Verkes (2006) noted that the cortisol findings were very
consistent, with significant increases in 11 of 12 studies,
whereas the only nonsignificant study had utilized a low
Table 1 Overview of 3,4-methylenedioxymethamphetamine acute-dose laboratory studies into oxytocin and psychosocial measures
Reference; drug conditions Oxytocin changes Psychosocial measures
Associations between oxytocin and
the prosocial measures
Dumont et al. (2009); 100 mg oral MDMA
and placebo
Oxytocin significantly increased Increased prosocial feelings Significant positive association
between oxytocin and prosocial
measures
Hysek et al. (2012); 125 mg oral MDMA
and placebo
Oxytocin significantly increased Overall bias towards positive mood
judgements, and away from negative
mood judgements
No association between oxytocin
and any psychosocial measure
Hysek et al. (2014); 125 mg oral MDMA
and placebo, with equal males and
females
Oxytocin significantly increased Emotional recognition impaired overall, and
emotional empathy improved. Complex
sex and emotional valence effects
No correlation between oxytocin and
any psychosocial measure
Schmid et al. (2014); 75 mg oral MDMA,
40 mg methylphenidate and placebo
Oxytocin significantly increased Enhanced empathy and increased feelings
of openness/trust
No correlation between oxytocin and
any emotional or sociocognitive
measure
Kuypers et al. (2014); 75 mg oral MDMA
oxytocin nasal spray and placebo
Borderline trend for increased oxytocin
(P=0.071, two-tailed)
Increased emotional empathy. No gains in
cognitive empathy or trust
No correlation between oxytocin and
emotional empathy or other
measures
Kirkpatrick et al. (2014b); 75 mg and
125 mg oral MDMA, nasal oxytocin and
placebo
Oxytocin significantly increased by
125 mg MDMA. Nonsignificant trend
with 75 mg dose
Increased euphoria and sociability after the
higher dosage
No correlation between oxytocin and
mood gains
MDMA, 3,4-methylenedioxymethamphetamine.
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dosage. To give some examples of these cortisol findings,
Mas et al. (1999) reported significant increases following
acute doses of both 75 and 125 mg oral MDMA. Pacifici
et al. (2001) reported significant increases in cortisol fol-
lowing both single and closely repeated doses of MDMA.
Harris et al. (2002) found that a low dose of 0.5 mg/kg led
to a cortisol increase of around 100%, whereas the higher
and more typical dose of 1.5 mg/kg led to an increase of
150% compared with baseline. Spaced dosing was
empirically investigated by Farre et al. (2004), who found
that each dose led to significant increases in cortisol.
Seibert et al. (2014) administered oral doses of 125 mg
MDMA to in-bed volunteers resting in a hospital setting.
Significant increases in cortisol, corticosterone and
11-dehydroxycorticosterone were found, with peak
effects 1–3 h after drug administration.
Neurohormonal changes have also been investigated in
real-world studies of dance clubbers. Parrott et al. (2008)
prospectively monitored recreational ecstasy/MDMA
users over successive weekends, when dance clubbing at
a city venue with the same group of friends. On one
weekend they partied as usual, whereas on the other they
abstained from MDMA (with order counterbalanced).
Saliva analyses confirmed MDMA in every participant
during their ‘normal’ weekend and its absence during the
weekend off MDMA. Dance clubbing while on MDMA
led to a peak increase of 800% in salivary cortisol,
whereas cortisol was not significantly changed during the
off MDMA weekend. This pronounced cortisol
enhancement was confirmed in another real-world study,
with more experienced drug users at weekend ‘house
parties’ (Parrott et al., 2007). There was a group mean
peak increase of 800% in cortisol when partying on
MDMA but again no significant change in cortisol when
partying off MDMA. Wolff et al. (2012) recorded cortisol
levels of dance clubbers before and after clubbing. Urine
analyses revealed that 21 had used MDMA, whereas 18
were nonusers. Postclubbing cortisol levels were sig-
nificantly higher in MDMA users compared with those in
nonusers, with a comparative increase of 110%. These
postclubbing samples were collected between 03:00 and
08:00 in the morning, and covered a time of post-MDMA
recovery (note: cortisol was not measured at the club,
when peak drug effects would be expected). Wolff et al.
(2012) also investigated genetic factors and found sig-
nificant associations between low activity in the COMT
genotype and heightened cortisol responses in both
groups. There was also an association between the
CYP2D2 genotype and heightened cortisol levels but
only in the MDMA subgroup. For an extended debate
about these real-world cortisol findings, see Parrott et al.
(2013) and Wolff and Aitchison (2013).
There are some interesting differences in the acute neuro-
hormonal effects of MDMA at dance clubs versus the
laboratory. Partying on ecstasy/MDMA led to peak increases
in cortisol of around 800%, whereas peak increases in the
laboratory studies were around 150–200%. The greater
neurohormonal response when dancing and partying may
reflect the combined effects of taking a central nervous
system stimulant drug in stimulatory conditions. Hence, it
has been suggested that prolonged physical exertion, loud
music and social crowding may potentiate the stimulatory
drug effects (Parrott et al., 2006). It may also be influenced
by other factors such as circadian rhythms (Herbert et al.,
2007), or differences in dosage levels. However, it should be
noted that in the study by Parrott et al. (2007) the more
experienced users took larger amounts of ecstasy/MDMA
than did the less experienced users in the study by Parrott
et al. (2008); yet both groups achieved similar peak increases
in cortisol. This self-titration of different doses may reflect
the development of chronic tolerance (review: Parrott, 2005);
yet it was interesting that both groups achieved similar peak
levels of cortisol. Whatever the reasons for the differences
between the laboratory and real-world findings, recreational
ecstasy/MDMA users certainly experience very high levels
of cortisol while partying.
Chronic MDMA and cortisol
Gerra et al. (2003) were the first to empirically investigate
the neurohormonal consequences of chronic ecstasy/
MDMA usage. They found significant differences
between long-term recreational ecstasy users and nonuser
controls, both in baseline cortisol and cortisol reactions to
a ‘psychosocial’ stressor. Gerra et al. (2003) concluded that
‘HPA basal hyperactivation and reduced responsiveness
to stress may represent a complex neuroendocrine dys-
function associated with MDMA use’. Cortisol can be
measured in hair samples (Kirschbaum et al., 2009; Stalder
and Kirschbaum, 2012), with 3-cm lengths providing an
index of neurohormonal activity over the previous
3 months. Parrott et al. (2014a) analysed hair samples of
101 young participants: light and heavier ecstasy/MDMA
users during the previous 3 months, and nonuser controls.
The recent heavy ecstasy/MDMA users had mean cortisol
levels 400% higher than that of nonuser controls, whereas
the recent light users showed a nonsignificant trend for
higher cortisol. These cortisol findings indicate that a high
level of psychobiological stress is being experienced by
regular recreational ecstasy/MDMA users. A high variance
of the heavy user group should also be noted, especially in
comparison with the low variance of the control group, as
it indicates considerable variation in their levels of psy-
chobiological stress.
The secretion of cortisol follows a regular diurnal rhythm
(Khoury et al., 2015; Stalder et al., 2016): the act of awa-
kening from sleep is followed by a cortisol peak around
30 min later. This pattern has been termed the cortisol
awakening response, where awakening in the morning
generated a peak 50–75% rise in plasma cortisol (Stalder
et al., 2016). The cortisol awakening response provides
neuroendocrinology research with a standard index for
the integrity of the HPA axis (Fries et al., 2009; Frokjaer
652 Behavioural Pharmacology 2016, Vol 27 No 8
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
et al., 2014; Khoury et al., 2015; Stalder et al., 2016). It has
been investigated with recreational ecstasy/MDMA users
in two recent studies. Wetherell and Montgomery (2014)
compared light and heavy ecstasy/MDMA users with
nonuser controls on a low-stress day and a high-stress day.
The cortisol awakening response was similar for all three
groups on the low-stress day but was significantly raised in
the heavy ecstasy user group on the high-stress day.
Cortisol levels before bedtime were also significantly raised
in both ecstasy/MDMA groups on the high-stress day.
Frokjaer et al. (2014) compared 18 drug-free recreational
ecstasy/MDMA users with 32 nonuser controls. The cor-
tisol awakening response was significantly higher in the
ecstasy/MDMA users, compared with controls (see figure 2
from Frokjaer et al., 2014). Furthermore, the degree of
enhancement of the cortisol awakening response was sig-
nificantly associated with greater prefrontal binding of the
serotonin transporter. To summarize, regular ecstasy/
MDMA users can display raised levels of cortisol both after
awakening and later in the diurnal cycle (Frokjaer et al.,
2014; Wetherell and Montgomery, 2014). They also
demonstrate significant increases in 3-month cortisol levels
in hair samples and altered cortisol reactivity to stress
(Gerra et al., 2003; Parrott et al., 2014a, 2014b). Khoury et al.
(2015) noted that mainstream cortisol research generated
two key measures: total cortisol and cortisol change/reac-
tivity. Both elements have been investigated in MDMA
research, and both show significant drug effects. Hence,
there are clear hormonal indications of HPA axis impair-
ments in recreational ecstasy/MDMA users.
In terms of functional implications, cortisol is involved in
many core areas for well-being, including homeostasis,
sleep, waking, appetite, memory, cognition, psychiatric
aspects and neuronal integrity. In an overview of the
nonpharmacological research, Herbert et al. (2007) noted
that high levels of corticosteroids were potentially dama-
ging to many of these core functions. Excess levels of
corticosteroids could damage the brain directly, or
increase its susceptibility to damage by other noxious
agents. These neuropsychobiological deficits are sum-
marized in Table 2. In another cortisol review, it was
noted that many of these same functions were also
affected in drug-free recreational ecstasy/MDMA users
(Parrott, 2009). Hence, these changes in cortisol might
play a contributory role in many of the adverse psycho-
biological effects of recreational ecstasy/MDMA
(Table 2). Since that review, further studies have gener-
ated further empirical evidence for drug-related func-
tional deficits (McCann et al., 2009, 2011; Brière et al.,
2012; Singer et al., 2013, 2016; Ogeil et al., 2011; Parrott,
2013a, 2013b, 2014; Taurah et al., 2014; Downey et al.,
2015). The relative contributory role of neurohormones
such as cortisol and oxytocin, and neurotransmitters such
as serotonin, dopamine and noradrenaline, is a complex
question. Most reviews have focussed on the role of
neurotransmission (Kish et al., 2010; Benningfield and
Cowan, 2013; Parrott, 2013b; Meyer, 2013; McCann and
Ricaurte, 2014; Taurah et al., 2014). However, cortisol
may also have a contributory role. Some of its effects will
be indirect, by modulating serotonergic neurotransmis-
sion, and hence affecting a wide variety of psychobiolo-
gical functions (Chaouloff, 2000; Frokjaer et al., 2014).
Other effects may be through alterations in the HPA axis,
with impaired homeostasis, disturbed sleep, increased
stress, fluctuating moods and other indices of increased
psychobiological vulnerability (McCann and Ricaurte,
2007; Parrott, 2009, 2013a, 2013b; Scholey et al., 2011;
Ogeil et al., 2011, 2013; Wetherell and Montgomery, 2012,
2014). Future studies may illuminate this complex issue.
Broad overview
Recent theoretical interest in the neurohormonal aspects
of MDMA has focussed mostly on oxytocin. Here the
proposed functional model is very clear: oxytocin is
thought to underlie the positive moods and prosocial
feelings engendered by recreational MDMA (McGregor
et al., 2008; White, 2014; Kamilar-Britt and Bedi, 2015).
In empirical support of this model, Dumont et al. (2009)
found a significant association between oxytocin release
and the prosocial feelings induced by MDMA.
Subsequent studies have also demonstrated increased
levels of oxytocin, and they have often been accom-
panied by increases in prosocial behaviours. However,
against this model, these same studies have consistently
failed to demonstrate an association between psychoso-
cial measures and increases in oxytocin levels (Table 1).
The absence of the predicted correlations has been noted
by every research group in this field. Hysek et al. (2014)
commented that, although they found increases in oxy-
tocin and emotional cognition, ‘We found no correlation
between MDMA-induced endocrine and emotional
changes’. Kirkpatrick et al. (2014a, 2014b) compared the
effects of oral MDMA with nasal oxytocin, but they
noted that MDMA and oxytocin did not produce similar
effects. Kamilar-Britt and Bedi (2015) similarly concluded
that in humans the degree to which oxytocin was
involved in the prosocial effects of oxytocin remained
unclear.
These researchers have also debated potential explana-
tions for the absence of the expected association. The
difficulty of estimating central oxytocin levels from per-
ipheral measures has often been noted (Hysek et al.,
2014; Kamilar-Britt and Bedi, 2015; others). The practical
difficulties of researching nasal oxytocin in humans have
been outlined by Churchland and Winkielman (2012).
They noted that oxytocin was an unstable hormone, with
many diverse effects on body and brain. It was also
unclear whether nasal oxytocin reached the brain,
because of the intricacies of the blood–brain barrier.
Leng and Ludwig (2016) similarly noted that little of
intranasally administered oxytocin reached the cere-
brospinal fluid, whereas peripheral concentrations could
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be increased substantially. Another issue is the broadness
and diversity of the concept of psychosocial benefits as it
can encompass a wide range of emotions and cognitions.
Indeed, this may be a crucial factor in explaining the
difference between the animal and human findings. Each
person can respond to ecstasy/MDMA in different ways,
some more emotionally, others more cognitively, and this
will increase the random/error variance for any grouped
data. Other potential explanatory factors might include
group differences in ethnicity or sex, perceived stresses
during testing, while genetic factors also need to be
studied. Nevertheless, given the extensive preclinical
and other evidence for oxytocin and prosocial behaviours
(Kovacs et al., 1998; McGregor et al., 2008; McGregor and
Bowen, 2012; Churchland and Winkielman, 2012;
Broadbear et al., 2014), the absence of the expected
association in human MDMA research (Table 1) does
remain somewhat surprising.
Turning to cortisol, here the empirical findings are clear.
An acute dose of MDMA can increase cortisol levels both
in the laboratory (Dumont and Verkes, 2006) and in the
real world of dance clubbers (Parrott et al., 2008). Cortisol
is involved in basic metabolic activation and is integral to
the sympathomimetic alertness caused by stimulant
drugs. It increases the delivery of increased energy sup-
plies to the muscles and facilitates prolonged dancing.
However, excessive stimulation is also a factor in the
acute hyperthermia and other acute medical problems
that develop in some recreational uses (Hall and Henry,
2006). MDMA can impair hypothalamic thermoregula-
tion and lead to increased body temperature, both in the
laboratory (Freedman et al., 2005) and in recreational
users (Morefield et al., 2009; Parrott and Young, 2014). In
placebo-controlled laboratory studies the degree of
overheating is related to MDMA dosage (review: Parrott,
2012), whereas in real-world studies it can be quite
variable, with some studies showing slight changes and
others revealing large thermal increases. Morefield et al.
(2009) reported a group mean peak body temperature
increase of + 1.1°C in 41 Australian party-goers on
MDMA. Parrott and Young (2014) reported a group mean
peak increase of + 1.2°C in 32 Welsh dance clubbers on
ecstasy/MDMA. Hyponatraemia, or low sodium levels in
the blood, is another commonly observed abreaction. In a
biochemical study of Dutch ravers (Van Dijken et al.,
2013), hyponatraemia was found in 25% of female
MDMA users, compared with 3% of male users. This
indicates an interesting sex difference in reactivity to
MDMA. Whether this reflects a broader influence of sex
on the HPA axis remains to be empirically determined.
In relation to chronic drug effects, Herbert et al. (2007)
noted that ‘Corticosteroids are an essential component of
the body’s homeostatic system’, and that the regular
experience of psychobiological overactivation and stress
was cumulatively damaging to the organism, citing Hans
Selye’s classic studies into cortisol and stress (Selye,
1956). The bioenergetic stress model for recreational
ecstasy notes that the regular experience of over-
activation and biological stress may be cumulatively
damaging to the organism (Parrott, 2006). Furthermore,
the degree of psychophysiolgical overactivation will
depend on both the extent of drug stimulation and
environmental costimulation. Hence, ‘Dances and raves
may help to boost the acute effects of ecstasy/MDMA.
But however, this may also make them more problematic
in the longer term’ (Parrott, 2006, 2009). The multi-
factorial types of psychobiological and neurocognitive
damage caused by recreational ecstasy/MDMA were
summarized earlier. Cortisol may play a key modulatory
role by altering the HPA axis, damaging homeostasis, and
exacerbating any underlying serotonergic changes
(Parrott, 2013a, 2013b).
Future research
In future research, the functional aspects of oxytocin
should be investigated using a wider battery of assess-
ment measures. Current research has focussed almost
exclusively on prosocial measures. This needs to be
widened by including measures of more negative moods
and behaviours. It was earlier noted that placebo-
controlled studies have found that acute MDMA can
generate significant feelings of anxiety, loneliness and
Table 2 Psychobiological functions affected by cortisol and ecstasy/3,4-methylenedioxymethamphetamine: a broad overview (after Parrott
2009, with some updated references)
Psychobiological functions Cortisol MDMA/ecstasy
Memory: task performance deficits Backhaus et al., 2006 McCann and Ricaurte, 2014
Memory: subjective complaints Wolf et al., 2005 Rodgers et al., 2003
Higher cognition: performance deficits McMorris et al., 2006 Fox et al., 2002
Other cognitive task impairments Oei et al., 2006 Montgomery et al., 2010
Sleep and circadian rhythm Stalder et al., 2016 Ogeil et al., 2011
Eating and feeding Nieuwenhuizen and Rutters, 2008 Turner et al., 1998
Depression Nemeroff and Vale, 2005 Brière et al., 2012
Impulsivity Fishbein et al., 1989 Taurah et al., 2014
Other clinical disorders Strohle and Holsboer 2003 Parrott, 2013a,b
Oxidative stress McEwan 2006 Zhou et al., 2003
Hippocampal changes Nagaraja et al., 2007 Jacobsen et al., 2004
Neuronal damage Herbert et al., 2007 Benningfield and Cowan, 2013
MDMA, 3,4-methylenedioxymethamphetamine.
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depression (Liechti et al., 2001; Bedi et al., 2010; Parrott
et al., 2011; Kirkpatrick et al., 2012), whereas recreational
ecstasy/MDMA users occasionally experience feelings of
anxiety and panic (Cohen, 1998). Furthermore, recrea-
tional users who reported taking the drug only a few
times described weak mood gains with their first
experience (Parrott, 2010). This helps explain why they
did not take it again, and confirms that the mood reac-
tions to MDMA are more variable than is commonly
portrayed (extensive literature review in Parrott, 2007). It
is widely accepted that oxytocin is involved in affiliative
behaviours (McGregor et al., 2008; Broadbear et al., 2014).
Yet, does oxytocin selectively boost only positive mood
states, or might it also be involved in the intensification
of negative moods? Might differences in oxytocin reac-
tivity help explain some of the variation in mood reac-
tions to MDMA? Indeed, there may be many factors that
influence these mood state changes.
Two further areas for future research are potential effects
of MDMA on sex and pregnancy through alterations in
oxytocin or other neurohormones. Emanuele et al. (2006)
suggested that the increased oxytocin levels revealed by
Wolff et al. (2006) might account for the increased libido
and sexual behaviours of MDMA users. The recreational
use of MDMA is associated with enhanced sexual plea-
sure and increased sexual riskiness (Theall et al., 2006;
May and Parrott, 2015). In a laboratory study of reactions
to erotic stimuli, increased sexual arousal was found after
40 mg oral methylphenidate, although surprisingly this
did not occur after 75 mg oral MDMA (Schmid et al.,
2015) (note, however, the low dose of 75 mg MDMA, as
significant effects might have occurred after a higher
dose). Another potential area for future research is human
pregnancy, given that oxytocin has important functions in
birth. Oxytocin promotes uterine contractions during
labour, and milk ejection during lactation (McGregor
et al., 2008). Hence, another key question is whether
MDMA leads to chronic changes in oxytocin following
repeated drug usage. Chronic oxytocin changes have
been demonstrated in laboratory animals, and human
research is clearly needed (McGregor and Bowen, 2012).
Women who regularly used ecstasy/MDMA during their
first trimester of pregnancy gave birth to babies with
significant psychomotor impairments (Singer et al., 2013,
2016). Future human studies should monitor levels of
oxytocin, cortisol and other neurohormones during
pregnancy and following birth. Cortisol levels normally
increase during the third trimester (Kirschbaum et al.,
2009); hence, the extent of this increase should also be
investigated in drug-using mothers. Incidentally, the
recreational MDMA-using mothers in the studies of
Singer et al. (2012, 2016) reported heightened depression
when taking MDMA, which reduced to normal levels
after ecstasy cessation (Turner et al., 2014). Hence, it
would be interesting to replicate this prospective
pregnancy study using a full battery of neurohormonal
measures.
Another topic for future research is whether oxytocin
might prove useful as pharmacotherapy for drug depen-
dency. McGregor and Bowen (2012) reviewed the evi-
dence for oxytocin modulation of acute and chronic drug
effects, especially those related to affiliative behaviours
and reinforcement/reward. Most evidence was pre-
clinical, although they noted supportive human research
findings. The core suggestion was that oxytocin might
facilitate the treatment of alcohol, opiate and other forms
of drug dependency. McGregor and Bowen (2012) noted
that oxytocin ‘Has fascinating potential to reverse the
corrosive effects of long-term drugs abuse on social
behaviour and to perhaps inoculate against future vul-
nerability to addictive disorders’. Another potential
research area is oxytocin-assisted pharmacotherapy for
post-traumatic stress disorder. Some studies of MDMA-
assisted pharmacotherapy have been undertaken, and
they have debated the putative role of oxytocin (Greer
and Tolbert, 1986; Mithoefer et al., 2011; Doblin et al.,
2014). In critiques of this venture, I have raised several
psychobiological concerns over the clinical usage of
MDMA (Parrott, 2007, 2014a, 2014b, 2016). If oxytocin is
involved in the increase in prosocial feelings, then nasal
oxytocin might provide a safer alternative for drug-
assisted psychotherapy (McGregor and Bowen (2012);
Parrott, 2014a, 2016).
There are many intriguing questions regarding the psy-
chobiological functions of cortisol. In relation to acute
effects, how is this master neurohormone related to
energetic stress and overstimulation in recreational users?
How does it contribute to medical abreactions, such as
hyperthermia and hyponatraemia? More specifically, is
cortisol related to the degree of psychophysiological
overstimulation, and can this help to explain why some
users cope with the drug robustly and others develop
abreactions? Another area is the functional roles of other
neurohormones such as prolactin, vasopressin, proges-
terone and testosterone. Although they have been
investigated in several studies (Wolff et al., 2016; Parrott
et al., 2007, 2008; Hysek et al., 2014; Schmid et al., 2014;
Seibert et al., 2014), the empirical data are very limited.
The role of cortisol for everyday homeostasis and well-
being was noted earlier, with many suggestions for future
research. Another key question is the extent of func-
tional/structural recovery following drug cessation. This
is important for both neurotransmitters and neuro-
hormones. Frokjaer et al. (2014) noted that ‘Future
longitudinal studies are needed to determine the time
course of potential recovery of HPA axis function after
withdrawal from MDMA use’.
Finally, we need to investigate the dynamic inter-
relations among neurohormones. In neuropharmacology
research, there are extensive animal and human data on
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hormonal interactions (Carson et al., 2013; Evans et al.,
2014), and this information can be used to guide future
MDMA research. For the current topic, how are the
changes in cortisol related to those of oxytocin? Do they
alter in parallel, or are they more independent? If social
enhancement was due to synergistic increases in both
cortisol and oxytocin, this might explain why positive
moods tend to be optimized in socially arousing venues
such as dance clubs or raves (Parrott, 2014a, 2014b). Is
there variation in the ways they coalter, and, if so, might
these be reflected in their differing functional effects?
How are they influenced by the psychosocial situation
(Evans et al., 2014). One key hypothesis for future
research is that the prosocial effects of oxytocin may
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